Cargando…
晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展
Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone dee...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973289/ https://www.ncbi.nlm.nih.gov/pubmed/28103976 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.01.10 |
| _version_ | 1783326585221283840 |
|---|---|
| collection | PubMed |
| description | Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. This review aimed to summarize the advanced developments of targeted therapy for anaplastic lymphoma kinase (ALK) and other rare driver genes in NSCLC. |
| format | Online Article Text |
| id | pubmed-5973289 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59732892018-07-06 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 Zhongguo Fei Ai Za Zhi 综述 Targeted therapy was one of the major treatments in advanced non-small cell lung cancer (NSCLC) with positive driver genes. This area of research progresses day by day, with novel target discoveries, novel drug development, and use of novel combination treatments. Researchers have also undergone deep investigation about the molecular mechanisms underlying inherent or acquired resistance to these targeted therapies. This review aimed to summarize the advanced developments of targeted therapy for anaplastic lymphoma kinase (ALK) and other rare driver genes in NSCLC. 中国肺癌杂志编辑部 2017-01-20 /pmc/articles/PMC5973289/ /pubmed/28103976 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.01.10 Text en 版权所有©《中国肺癌杂志》编辑部2017 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 综述 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| title | 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| title_full | 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| title_fullStr | 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| title_full_unstemmed | 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| title_short | 晚期非小细胞肺癌ALK融合基因及其他少见驱动基因阳性靶向治疗进展 |
| title_sort | 晚期非小细胞肺癌alk融合基因及其他少见驱动基因阳性靶向治疗进展 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973289/ https://www.ncbi.nlm.nih.gov/pubmed/28103976 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.01.10 |
| work_keys_str_mv | AT wǎnqīfēixiǎoxìbāofèiáialkrónghéjīyīnjíqítāshǎojiànqūdòngjīyīnyángxìngbǎxiàngzhìliáojìnzhǎn AT wǎnqīfēixiǎoxìbāofèiáialkrónghéjīyīnjíqítāshǎojiànqūdòngjīyīnyángxìngbǎxiàngzhìliáojìnzhǎn |